biostudies-literatureRen BNational Natural Science Foundation of ChinaAlzheimer's AssociationDivision of Materials ResearchDivision of Chemical, Bioengineering, Environmental, and Transport Systems243-250https://www.ebi.ac.uk/biostudies/studies/S-EPMC6044715biostudies-literatureUnknown2(1)Cardiovascular disease (CVD) and Alzheimer's disease (AD) have a mutual cause-and-effect relationship, and they share some common risk factors. Although numerous Food and Drug Administration (FDA)-approved drugs have been developed for CVD treatment, no drugs are clinically available for AD treatment. Given the common disease-causing factors and links between the two diseases and the well-demonstrated drugs for CVD, we propose to re-examine the new potential of the existing CVD drugs as amyloid-β (Aβ) inhibitors. 3-Morpholinosydnonimine hydrochloride (SIN-1) is an FDA-approved drug for inhibiting platelet aggregation in CVD. Herein, we examine the inhibition activity of SIN-1 on the aggregation and toxicity of Aβ_1-42 using combined experimental and computational approaches. CollACS omegaIdentification of a New Function of Cardiovascular Disease Drug 3-Morpholinosydnonimine Hydrochloride as an Amyloid-β Aggregation Inhibitor.PMC60447152015-NIRG-3413721607475151009921528601Wang MZheng JLiang GZhang MLin YChen HHu RSun YJia LRen BfalseIdentification of a New Function of Cardiovascular Disease Drug 3-Morpholinosydnonimine Hydrochloride as an Amyloid-β Aggregation Inhibitor.Cardiovascular disease (CVD) and Alzheimer's disease (AD) have a mutual cause-and-effect relationship, and they share some common risk factors. Although numerous Food and Drug Administration (FDA)-approved drugs have been developed for CVD treatment, no drugs are clinically available for AD treatment. Given the common disease-causing factors and links between the two diseases and the well-demonstrated drugs for CVD, we propose to re-examine the new potential of the existing CVD drugs as amyloid-β (Aβ) inhibitors. 3-Morpholinosydnonimine hydrochloride (SIN-1) is an FDA-approved drug for inhibiting platelet aggregation in CVD. Herein, we examine the inhibition activity of SIN-1 on the aggregation and toxicity of Aβ_1-42 using combined experimental and computational approaches. Coll2017-01-01T00:00:00Z2017 Jan2025-04-05T09:52:25.81Z2019-03-26T23:47:32ZS-EPMC60447153002351410.1021/acsomega.6b00397